
Boston Sci expects $200M tariff hit, still raises guidance
HRS 2025 Growth in the first quarter for Boston Scientific Corp.’s blockbuster products, Farapulse and Watchman, pushed the company well over analysts’ expectations and gave management confidence to raise its guidance for the year to 15% to 17% up from 12. …